News Features After DanGer Shock’s Win in AMICS for Impella: What’s Next? Caitlin E. Cox May 02, 2024
News Features FFR’s Future: Negative Trials Spur Debate Over Technology’s Role Michael O'Riordan December 23, 2021
News Features Too Easy to Misconstrue: Is It Time to Ditch Periprocedural MI? Michael O'Riordan December 02, 2020
News Features Hospitals Plan Cautious Restart to Elective Procedures as COVID-19 Wanes Michael O'Riordan May 12, 2020
News Features ‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19 Michael O'Riordan April 07, 2020
News Features The Mystery of the Missing STEMIs During the COVID-19 Pandemic Shelley Wood April 02, 2020
News Features Trial by Twitter: How a 280-Character Count Is Reshaping Cardiology Michael O'Riordan March 03, 2020
News Features Year in Review: ISCHEMIA Tops Coronary News in 2019 but Other Trials Shine, Too Michael O'Riordan December 09, 2019
News Features Subtherapeutic Heparin: As Stories Multiply, Concerns Mount Yael L. Maxwell November 27, 2019
News Features Twitter Takes on the Times of India, but the Question Persists: Is Foregoing a Stent an Option? Shelley Wood April 30, 2019
News Features Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate Michael O'Riordan November 27, 2017
News Features Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen? Michael O'Riordan September 13, 2017
News Features Absorb in Europe: When, How, and by Whom the Beleaguered BVS Is Being Used After Restrictions Michael O'Riordan May 08, 2017
News Features Stents as Essential Medicine: India’s Cap on Stent Prices Could Have Ripples Around the Globe Shelley Wood May 05, 2017
News Features Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond Shelley Wood December 30, 2016
News Features Grumbling Over Bundling: Cardiologists React Warily to Plans for Lump-Sum Payments for Cardiac Care Caitlin E. Cox September 23, 2016
News Features The Bioresorbable Stent Story So Far: What Promise? What Price? Michael O'Riordan August 17, 2016